Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
1 raison identifiée
Praticien-chercheur
7 articles scientifiques publiés — formation continue solide
✨ Génération du profil synthétique IA en cours…
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Annals of medicine · 2022
Journal of cellular physiology · 2015
Tumor angiogenesis is accompanied by vasculogenesis, which is involved in the differentiation and mobilization of human bone marrow cells. In order to further characterize the role of vasculogenesis in the tumor growth process, the effects of FGF2 on the differentiation of human bone marrow AC133+ cells (BM‐AC133+) into vascular precursors were studied in vitro. FGF2, like VEGFA, induced progenitor cell differentiation into cell types with endothelial cell characteristics. SSR128129E, a newly discovered specific FGFR antagonist acting by allosteric interaction with FGFR, abrogated FGF2‐induced endothelial cell differentiation, showing that FGFR signaling is essential during this process. To assess the involvement of the FGF/FRGR signaling in vivo, the pre‐clinical model of Lewis lung carcinoma (LL2) in mice was used. Subcutaneous injection of LL2 cells into mice induced an increase of circulating EPCs from peripheral blood associated with tumor growth and an increase of intra‐tumoral vascular index. Treatment with the FGFR antagonist SSR128129E strongly decreased LL2 tumor growth as well as the intra‐tumoral vascular index (41% and 50% decrease vs. vehicle‐treated mice respectively, P < 0.01). Interestingly, SSR128129E treatment significantly decreased the number of circulating EPCs from the peripheral blood (53% inhibition vs. vehicle‐treated mice, P < 0.01). These results demonstrate for the first time that the blockade of the FGF/FGFR pathway by SSR128129E reduces EPC recruitment during angiogenesis‐dependent tumor growth. In this context, circulating EPCs could be a reliable surrogate marker for tumor growth and angiogenic activity. J. Cell. Physiol. 230: 43–51, 2015. © 2014 Wiley Periodicals, Inc.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Annals of medicine · 2022 · Journal Article
Cohen A, Vakharia SP, Netherland J, Frederique K
Journal of cellular physiology · 2015 · Journal Article
Fons P, Gueguen-Dorbes G, Herault JP, Geronimi F, et al.
The American Journal of dermatopathology · 2007 · Case Reports
Pierre-Alexandre J, François le P, Abdellah S, Karim T, et al.
The American journal of tropical medicine and hygiene · 2020 · Journal Article
Salam AP, Raberahona M, Andriantsalama P, Read L, et al.
Journal of cosmetic dermatology · 2024 · Journal Article
Wang Y, Niu Y, Ye C, He X, et al.
Brain sciences · 2020 · Journal Article
Maniscalco L, Frédérique BB, Roccella M, Matranga D, et al.
Journal of medical economics · 2018 · Journal Article
Grynberg M, Murphy C, Doré C, Fresneau L, et al.